BRPI0514254A - uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal - Google Patents

uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal

Info

Publication number
BRPI0514254A
BRPI0514254A BRPI0514254-7A BRPI0514254A BRPI0514254A BR PI0514254 A BRPI0514254 A BR PI0514254A BR PI0514254 A BRPI0514254 A BR PI0514254A BR PI0514254 A BRPI0514254 A BR PI0514254A
Authority
BR
Brazil
Prior art keywords
treatment
inflammatory diseases
cell
gastrointestinal tract
specific conjugates
Prior art date
Application number
BRPI0514254-7A
Other languages
English (en)
Inventor
Mladen Mercep
Milan Mesic
Linda Tomaskovic
Stribor Markovic
Original Assignee
Glaxosmithkline Zagreb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Zagreb filed Critical Glaxosmithkline Zagreb
Publication of BRPI0514254A publication Critical patent/BRPI0514254A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

USO DE CONJUGADOS CéLULA-ESPECìFICOS PARA O TRATAMENTO DE DOENçAS INFLAMATóRIAS DO TRATO GASTRINTESTINAL. A presente invenção está direcionada a métodos para a prevenção e tratamento de doenças, distúrbios, e condições inflamatórias do trato gastrintestinal mediante administrar a um paciente com necessidade de tal tratamento compostos conjugados de acordo com a fórmula (VII) possuindo baixa biodisponibilidade oral, ou seus sais, pró-drogas, ou solvatos farmaceuticamente aceitáveis: onde M representa uma subunidade macrolida que possui a propriedade de acumulação nas células inflamatórias, T representa uma subunidade antiinflamatória que pode ser um esteróide ou um não esteróide (fração não-esteroidal) derivada de uma droga não esteroidal com atividade antiinflamatória, analgésica e/ou antipirética (NSAID) e L representa um ligante que liga de modo covalente M e T. A presente revelação está também direcionada a composições farmacêuticas contendo compostos conjugados de fórmula (VII) possuindo baixa biodisponibilidade oral.
BRPI0514254-7A 2004-08-12 2005-08-10 uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal BRPI0514254A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60108704P 2004-08-12 2004-08-12
US60331504P 2004-08-19 2004-08-19
PCT/IB2005/002406 WO2006018698A2 (en) 2004-08-12 2005-08-10 Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract

Publications (1)

Publication Number Publication Date
BRPI0514254A true BRPI0514254A (pt) 2008-06-03

Family

ID=35602235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514254-7A BRPI0514254A (pt) 2004-08-12 2005-08-10 uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal

Country Status (13)

Country Link
US (1) US20060035845A1 (pt)
EP (1) EP1778292A2 (pt)
JP (1) JP2008509899A (pt)
KR (1) KR20070046917A (pt)
AU (1) AU2005273592A1 (pt)
BR (1) BRPI0514254A (pt)
CA (1) CA2576291A1 (pt)
IL (1) IL181240A0 (pt)
MA (1) MA28809B1 (pt)
MX (1) MX2007001669A (pt)
NO (1) NO20071244L (pt)
RU (1) RU2007108544A (pt)
WO (1) WO2006018698A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282678B2 (en) 2002-11-13 2012-10-09 Allium Medical Solutions Ltd. Endoluminal lining
JP2008517993A (ja) * 2004-10-27 2008-05-29 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 抗炎症作用を有するコンジュゲート
US8133268B2 (en) 2007-05-30 2012-03-13 Cordis Corporation Stent/fiber structural combinations
WO2010045180A1 (en) 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
JP5945868B2 (ja) * 2010-05-25 2016-07-13 センヤン トンリァン グループ カンパニー，リミテッド レボイソバレリルスピラマイシンｉ、ｉｉ又はｉｉｉとその製剤、調製方法及び応用
EP2578596B1 (en) * 2010-05-25 2017-04-19 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPH07103148B2 (ja) * 1991-12-16 1995-11-08 株式会社ディ・ディ・エス研究所 アントラサイクリン−マクロライド複合体
HRP20010018A2 (en) * 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003215245A1 (en) * 2002-02-15 2003-09-09 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003211113B2 (en) * 2002-02-15 2007-08-09 Merckle Gmbh Antibiotic conjugates
NZ535354A (en) * 2002-02-15 2008-01-31 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
ES2325495T3 (es) * 2002-07-08 2009-09-07 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Moleculas hibridas de macrolidos con moleculas anti-inflamatorias esteroideas y no esteroideas.
CA2489398A1 (en) * 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
RU2330858C2 (ru) * 2002-07-08 2008-08-10 Глаксомитклайн Истраживацки Центар Загреб Д.О.О. Новые соединения, составы и способы лечения воспалительных заболеваний и состояний
HRP20030324A2 (en) * 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect

Also Published As

Publication number Publication date
NO20071244L (no) 2007-04-17
MX2007001669A (es) 2007-04-10
EP1778292A2 (en) 2007-05-02
IL181240A0 (en) 2007-07-04
JP2008509899A (ja) 2008-04-03
RU2007108544A (ru) 2008-09-20
AU2005273592A1 (en) 2006-02-23
KR20070046917A (ko) 2007-05-03
US20060035845A1 (en) 2006-02-16
CA2576291A1 (en) 2006-02-23
MA28809B1 (fr) 2007-08-01
WO2006018698A3 (en) 2006-12-28
WO2006018698A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
BRPI0514254A (pt) uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
CY1112499T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
BRPI0509863A (pt) liberação de fármaco para fundo de olho
BR0316027A (pt) Formulações de toxina botulina para administração oral
WO2008010222A3 (en) Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
BRPI0518266A8 (pt) Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
WO2007009539A3 (en) Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
CY1118263T1 (el) Φλουρμπιπροφαινη ελεγχομενης εκλυσης και μυοχαλαρωτικοι συνδιασμοι
AR061169A1 (es) Formulaciones farmaceuticas de fenilferina y composiciones para su absorcion en el colon
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
AR073077A1 (es) Uso de dabigatran. compuesto. composicion farmaceutica-
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
BRPI0714466B8 (pt) derivados de sulfeto de hidrogênio de fármacos anti-inflamatórios não esteroidais, e composição farmacêutica.
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
JP2009535370A5 (pt)
WO2005035485A3 (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
TR200703092A1 (tr) Flurbiprofen ve kas gevşetici kombinasyonları

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/7048 (2006.01), A61K 31/7052 (2006.01), A6